StockNews.AI
MRNA
StockNews.AI
172 days

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

1. Moderna's RSV vaccine mRESVIA receives marketing authorization in the UK. 2. This marks a significant milestone in Moderna's respiratory disease initiatives.

2m saved
Insight
Article

FAQ

Why Bullish?

The approval of mRESVIA demonstrates Moderna's continued innovation and revenue opportunities, similar to past vaccine approvals affecting stock positively.

How important is it?

The launch of mRESVIA creates additional revenue streams and strengthens Moderna's market position, critical for investor sentiment.

Why Short Term?

The immediate market reaction could favor MRNA's stock as investors respond to the successful approval.

Related Companies

NVAXPFEJNJ
mRESVIA ® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. "The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Related News